表紙
市場調查報告書

北美的血糖儀市場(2012年∼2024年)

North America Blood Glucose Monitoring Market - Growth, Trends, and Forecast (2012 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 808265
出版日期 內容資訊 英文 75 Pages
商品交期: 2-3個工作天內
價格
北美的血糖儀市場(2012年∼2024年) North America Blood Glucose Monitoring Market - Growth, Trends, and Forecast (2012 - 2024)
出版日期: 2019年02月01日內容資訊: 英文 75 Pages
簡介

北美成為糖尿病的高罹患率地區。WHO報告2015年世界有160萬人因糖尿病死亡。

本報告提供北美的血糖儀市場調查,市場概要,各類別、各國市場規模的變化與預測,市場成長要素及阻礙因素分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 調查成果
  • 前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第5章 市場區隔

  • 市場分析:血糖自我測量儀
    • 各零件
      • 血糖儀
      • 測試紙
      • 採血針
    • 各終端用戶
      • 醫院
      • 個人
  • 市場分析:持續血糖儀
    • 各零件
  • 各地區
    • 北美
      • 美國
      • 加拿大

第6章 市場指標

  • 第一型糖尿病人口(實在數值、預測值)
  • 第二型糖尿病人口(實在數值、預測值)

第7章 競爭情形

  • 企業簡介
    • Abbott Diabetes Care
    • Roche
    • Johnson & Johnson
    • Dexcom
    • Medtronic
    • Arkray
    • Ascensia Diabetes Care
    • Agamatrix Inc.
    • Bionime Corporation
    • Acon
    • Medisana
    • Trivida
    • Rossmax
  • 企業佔有率分析
    • Roche
    • Johnson & Johnson
    • Abbott Diabetes Care
    • Dexcom
    • Medtronics
    • 其他

第8章 市場機會與未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 52163

Market Overview

The countries in the North American region show a high prevalence of diabetes. According to WHO in 2015, approximately 1.6 million deaths were attributed directly to diabetes on a global scale.

Approximately 2.2 million deaths were caused due to high blood glucose in 2012. According to the ADA (American Diabetes Association), the total assessed cost for diagnosed diabetes in 2017 was USD 327 billion, which is inclusive of USD 237 billion in direct medical costs and USD 90 billion in augmented productivity.

For the cost categories analyzed, care for people with diagnosed diabetes adds up to USD 1 in every USD 4 spent for healthcare in the United States, and more than 50% of that expenditure is directly accountable to diabetes.

The self-monitoring blood glucose systems market has increased more because diabetic people have to test their glucose levels throughout the day.

As studied in several clinical trials, diabetic patients with T1DM have been shown to have better glycemic control, in comparison to when glucometer was used for routine self-monitoring blood glucose.

Scope of the Report

The North American blood glucose monitoring market has been segmented into glucometer devices, test strips, and lancets. The glucometer devices segment is further segmented into hospital use and home use. North America BGM report also covers the Continuous glucose monitoring market, and it is segmented into the receiver and sensor. In the report, North America is segmented into the United States, Canada, and Rest of North America.

Key Market Trends - The Blood Glucose Test Strips Revenue Consists of up to 83% Share in the Self-monitoring Blood Glucose Market

Type 1 diabetic patients should test their blood glucose at least three times a day, based on which the administered insulin dosages alter accordingly.

The test strip is a one-time use entity, and therefore, the volume of the test strip sold per year is high, as compared to the self-blood glucose meter.

The test strip market held 83.3% of the self-blood glucose monitoring market in 2018.

CGM proves to be an instrumental tool for patients relying on insulin pumps or multiple daily injections (MDI) therapy, as it helps in the improvement of glycemic balance without aggregating the danger for severe hypoglycemia.

The United States Leads the Blood Glucose Monitoring Market

In 2018, the United States held the largest share in the blood glucose monitoring market, due to the large patient pool and broader acceptance of advanced technologies. The Increase in the blood glucose monitoring market is due to the rise in diabetes population in all age groups.

The market value in the United States is expected to cross USD 11 billion by 2024. Diabetes-related complications are mostly due to poor glucose control.

In the United States, the BGM Market is expected to record an approximate CAGR of 13% till 2024. Glucometers are now portable and accurate to use.

Also, other factors, such as technological innovations and advances, give much convenience in measuring blood glucose levels. One such advancement is in monitoring the blood glucose levels established with continuous glucose monitoring devices.

Competitive Landscape

The North American blood glucose monitoring market was dominated by few major players in 2018, like Dexcom, Abbott, and Medtronic. It is expected that a new player may enter the market during the forecast period. In the United States, Dexcom holds more than 65% of the market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 Market Segmentation

  • 5.1 Self-Monitoring Blood Glucose Devices
    • 5.1.1 By Component (Value and Volume, 2012 - 2024)
      • 5.1.1.1 Glucometer Devices
      • 5.1.1.2 Test Strips
      • 5.1.1.3 Lancets
    • 5.1.2 By End User
      • 5.1.2.1 Hospital (Value and Volume, 2012 - 2024)
      • 5.1.2.1.1 Glucometer Devices
      • 5.1.2.1.2 Test Strips
      • 5.1.2.1.3 Lancets
      • 5.1.2.2 Personal (Value and Volume, 2012 - 2024)
      • 5.1.2.2.1 Glucometer Devices
      • 5.1.2.2.2 Test Strips
      • 5.1.2.2.3 Lancets
  • 5.2 Continuous Blood Glucose Monitoring
    • 5.2.1 By Component (Value and Volume, 2012 - 2024)
      • 5.2.1.1 Sensors
      • 5.2.1.2 Receivers
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States (Value and Volume, 2012 - 2024)
      • 5.3.1.1.1 Self-Monitoring Blood Glucose
      • 5.3.1.1.1.1 By Component (Glucometer Device, Test strips, Lancets)
      • 5.3.1.1.1.2 By End User (Hospital and Home)
      • 5.3.1.1.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.3.1.1.2 Continuous Glucose Monitoring
      • 5.3.1.1.2.1 By Component (Sensors and Receivers)
      • 5.3.1.1.2.2 By Company (Dexcom, Abbott, Medtronics and Others)
      • 5.3.1.2 Canada (Value and Volume, 2012 - 2024)
      • 5.3.1.2.1 Self-Monitoring Blood Glucose
      • 5.3.1.2.1.1 By Component (Glucometer Device, Test strips, Lancets)
      • 5.3.1.2.1.2 By End User (Hospital and Home)
      • 5.3.1.2.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.3.1.2.2 Continuous Glucose Monitoring
      • 5.3.1.2.2.1 By Component (Sensors and Receivers)
      • 5.3.1.2.2.2 By Company (Dexcom, Abbott, Medtronics and Others)
      • 5.3.1.3 Rest of North America (Value and Volume, 2012 - 2024)
      • 5.3.1.3.1 Self-Monitoring Blood Glucose
      • 5.3.1.3.1.1 By Component (Glucometer Device, Test strips, Lancets)
      • 5.3.1.3.1.2 By End User (Hospital and Home)
      • 5.3.1.3.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
      • 5.3.1.3.2 Continuous Glucose Monitoring
      • 5.3.1.3.2.1 By Component (Sensors and Receivers)
      • 5.3.1.3.2.2 By Company (Dexcom, Abbott, Medtronics and Others)

6 MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population (2012-2024)
  • 6.2 Type-2 Diabetes Population (2012-2024)

7 COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Abbott Diabetes Care
    • 7.1.2 Roche
    • 7.1.3 Johnson & Johnson
    • 7.1.4 Dexcom
    • 7.1.5 Medtronic
    • 7.1.6 Arkray
    • 7.1.7 Ascensia Diabetes Care
    • 7.1.8 Agamatrix Inc.
    • 7.1.9 Bionime Corporation
    • 7.1.10 Acon
    • 7.1.11 Medisana
    • 7.1.12 Trivida
    • 7.1.13 Rossmax
  • 7.2 COMPANY SHARE ANALYSIS
    • 7.2.1 Roche
    • 7.2.2 Johnson & Johnson
    • 7.2.3 Abbott Diabetes Care
    • 7.2.4 Dexcom
    • 7.2.5 Medtronics
    • 7.2.6 Others

8 MARKET OPPORTUNITES AND FUTURE TRENDS